Turmeric is the dried, ground rhizome (underground stem) of Curcuma longa, a plant in the ginger family. It is a common cooking spice and food coloring. As a supplement it is sold mainly for its yellow pigments, the curcuminoids, of which curcumin is the best known. People take it for joint pain, recovery after exercise and general “anti-inflammatory” purposes.
The single most important fact is that curcumin is very poorly absorbed. In a dose-escalation study, no curcumin was found in the blood after single doses of up to 8,000 mg. This led to a market of “enhanced bioavailability” products. Those enhanced products are also the ones most often linked to the main safety signal: rare but sometimes severe liver injury. A separate problem affects the spice itself, which is sometimes adulterated with the lead pigment lead chromate.
This page summarizes what clinical trials, NIH resources and published case series report. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Type | Botanical; spice and dietary supplement |
| Source | Rhizome of Curcuma longa (ginger family) |
| Main active compounds | Curcuminoids, ≈1–6% of turmeric by dry weight |
| Route | Oral |
| Studied doses | Single doses of 500–12,000 mg curcuminoids in safety and kinetics studies; knee osteoarthritis trials lasting up to 16 weeks |
| Absorption | Free curcumin undetectable in most people at 500–8,000 mg single doses |
| Half-life | Free curcumin too low to measure; its glucuronide and sulfate metabolites ≈6.8 h after 10–12 g |
| US status | Sold as a food and dietary supplement; not approved as a drug for any disease |
| Main safety signals | Idiosyncratic liver injury (often with high-bioavailability products); lead chromate adulteration of the spice |
| WADA status | Not listed on the 2026 Prohibited List |
What it is
Turmeric’s main constituents are diarylheptanoids that occur together as a mixture called curcuminoids. They make up about 1–6% of turmeric by dry weight (Nelson et al., J Med Chem 2017). Most extracts, and even many products sold as “curcumin,” contain three of them:
| Curcuminoid | Typical share of a crude extract |
|---|---|
| Curcumin | 60–70% |
| Demethoxycurcumin | 20–27% |
| Bisdemethoxycurcumin | 10–15% |
Products therefore differ a great deal. A capsule of ground turmeric contains only a few percent curcuminoids. A standardized extract can contain far more, and formulated products add carriers, oils or piperine (from black pepper) to raise absorption.
In laboratory studies curcumin appears to act on a very wide range of targets, from inflammatory signaling to amyloid fibrils. Whether those findings are real is one of the main questions about this compound (see the medicinal chemistry critique below).
Pharmacokinetics
Why curcumin is poorly absorbed
Several properties work against oral curcumin (Nelson et al., J Med Chem 2017):
- Very low water solubility, estimated at 1–10 μg/mL at neutral pH.
- Chemical instability. In neutral buffer at room temperature, half of the parent compound is lost in about 20 minutes. At 37 °C and pH 7.2 the reported half-life is under 10 minutes. It also breaks down in light.
- Poor gut permeability in standard cell-culture models (Caco-2 cells).
- Rapid metabolism. Whatever is absorbed is quickly converted to glucuronide and sulfate conjugates in the gut wall and liver.
Two human studies show the result:
| Study | Design | Finding |
|---|---|---|
| Lao et al., BMC Complement Altern Med 2006 | 24 healthy volunteers; single doses of 500–12,000 mg of a standardized curcuminoid powder | No curcumin detected in serum at 500–8,000 mg; low levels in 2 people at 10,000 or 12,000 mg |
| Vareed et al., Cancer Epidemiol Biomarkers Prev 2008 | 12 healthy volunteers; single 10 g or 12 g doses | Free curcumin detected in only 1 subject; glucuronide and sulfate conjugates found in all. Conjugate peak ≈1.7–2.3 μg/mL at ≈3.3 h; half-life ≈6.8 h |
So the “half-life” usually quoted for oral curcumin is really the half-life of its metabolites. Free curcumin itself is mostly below the detection limit.
Enhanced-bioavailability formulations
Manufacturers have tried several ways around this problem. Each study below compared a formulation against plain curcumin in healthy volunteers:
| Approach | Study | Reported increase vs plain curcumin |
|---|---|---|
| Piperine 20 mg with curcumin 2 g | Shoba et al., Planta Med 1998 | Bioavailability up 2000%; curcumin alone was undetectable or very low |
| Micronized powder (500 mg curcuminoids) | Schiborr et al., Mol Nutr Food Res 2014 | AUC 9-fold higher (23 subjects, crossover) |
| Liquid micelles (500 mg curcuminoids) | Schiborr et al., Mol Nutr Food Res 2014 | AUC 185-fold higher; 277-fold in women, 114-fold in men |
| Phospholipid complex (“phytosome”) | Jäger et al., Nutr J 2014 | Total curcuminoids 7.9-fold higher (12 subjects, crossover) |
| Curcumin with turmeric volatile oils | Jäger et al., Nutr J 2014 | 1.3-fold higher |
| Hydrophilic carrier with cellulose derivatives | Jäger et al., Nutr J 2014 | 45.9-fold higher |
These numbers need careful reading:
- The studies are not comparable. They used different doses, assays, sampling times and comparators, and some measured total curcuminoids plus metabolites rather than free curcumin.
- Some are manufacturer-funded. The Jäger study was financially supported by the maker of the best-performing product.
- More absorption is not proven benefit. None of these studies measured a clinical outcome.
- More absorption may mean more risk. The Italian and US liver-injury reports below involved many high-bioavailability or piperine-containing products.
The medicinal chemistry critique (Nelson 2017)
In 2017 a group of medicinal chemists published a detailed review of curcumin in the Journal of Medicinal Chemistry (Nelson et al., J Med Chem 2017). They concluded that curcumin is “an unstable, reactive, nonbioavailable compound” and a highly improbable lead for drug development. Their main arguments:
- It is a PAINS compound. PAINS (pan-assay interference compounds) are molecules that look active in many laboratory assays because they interfere with the test itself rather than acting on a specific target. The authors wrote that curcumin shows all known PAINS-type behaviors, which they listed as:
- covalent labeling of proteins;
- metal chelation;
- redox reactivity;
- aggregation;
- membrane disruption;
- fluorescence interference;
- breakdown into other compounds.
- It is an IMPS candidate. IMPS (“invalid metabolic panaceas”) are natural compounds that appear to do almost everything in the literature but perform poorly as real drug leads.
- The tested material is often not what it seems. Many studies did not confirm the purity of their “curcumin” or that it survived the assay. Given its minutes-long half-life in buffer, reported activity may come from degradation products.
- Lab activity often occurs at concentrations above its aggregation threshold and without counterscreens for assay interference.
- Clinical trials have not delivered. The authors counted 135 registered trials of curcuminoids and stated that “no double-blinded, placebo controlled clinical trial of curcumin has been successful.” They added that delivery systems that raise blood levels “could also conceivably narrow its therapeutic window.”
The authors did not rule out that whole turmeric could have some health effect. Their point was that the large in-vitro literature on curcumin is a weak basis for clinical claims. Since 2017, some randomized trials have reported positive results on symptom outcomes such as knee pain (below), but none has led to drug approval.
Regulatory status
- United States. Turmeric is a food and is sold as a dietary supplement. Supplements are not approved by the FDA before sale (NCCIH). Neither turmeric nor curcumin is approved as a drug for any disease. Nelson et al. note that the FDA responded with “no questions” to one company’s GRAS (generally recognized as safe) notice for curcuminoids as a food ingredient at up to 20 mg curcumin per serving, without making its own GRAS determination.
- Sport. Neither turmeric nor curcumin is named on the WADA 2026 Prohibited List.
What the research shows
The NIH’s National Center for Complementary and Integrative Health summarizes the evidence this way: “We don’t know enough to definitively conclude if turmeric or curcumin is beneficial for any health purposes” (NCCIH). It describes the knee osteoarthritis evidence as initially positive but in need of higher-quality trials, and notes early research in fatty liver disease and cancer-treatment mouth sores (oral mucositis).
Knee osteoarthritis
Knee osteoarthritis is the best-studied use. A 2021 meta-analysis pooled 16 randomized trials with 1,810 adults, lasting up to 16 weeks (Wang et al., Curr Rheumatol Rep 2021):
| Comparison | Outcome | Effect (SMD, 95% CI) |
|---|---|---|
| Turmeric extract vs placebo (11 trials) | Knee pain | −0.82 (−1.17 to −0.47) |
| Turmeric extract vs placebo | Physical function | −0.75 (−1.18 to −0.33) |
| Turmeric extract vs NSAIDs (5 trials) | Pain and function | Similar effects |
SMD (standardized mean difference) expresses effects in units of standard deviation; negative values favor turmeric. Heterogeneity between trials was very high (I² of 86–90%), risk of bias was moderate, and benefit was smaller in people with higher BMI. The authors concluded there is “some uncertainty about the true effect.” No differences were found in blood markers or imaging.
One frequently cited example is a double-blind randomized trial of 70 people with knee osteoarthritis and joint swelling on ultrasound, given two capsules daily of a Curcuma longa extract or placebo for 12 weeks (Wang et al., Ann Intern Med 2020). It was co-funded by the extract’s manufacturer.
| Outcome | Extract vs placebo |
|---|---|
| Knee pain (VAS, primary) | −9.1 mm (95% CI −17.8 to −0.4) |
| Effusion-synovitis volume on MRI (primary) | No change: 3.2 mL (95% CI −0.3 to 6.8) |
| WOMAC knee pain (secondary) | −47.2 mm (95% CI −81.2 to −13.2) |
| Cartilage composition (T2 relaxation time) | No change |
| Adverse events | 39% vs 53% (not significantly different) |
The pain benefit was modest, and the extract did not change the joint swelling it was designed to target.
Exercise-induced muscle damage and soreness
Meta-analyses of small trials disagree:
| Meta-analysis | Finding |
|---|---|
| Fang and Nasir, Phytother Res 2021 | Creatine kinase (a muscle-damage marker) −48.5 IU/L (95% CI −80.7 to −16.4); soreness score −0.48 (95% CI −0.75 to −0.20) |
| Oxley and Peart, Nutr Health 2024 | 16 studies; no statistically significant effect on muscle damage, soreness or inflammation at any time point from 0 to 96 h after exercise |
The evidence for faster recovery is therefore inconsistent, and the trials are small and use many different products and doses.
Side effects and risks
Common side effects
Conventional oral turmeric or curcumin (not modified to raise absorption) is described by NCCIH as likely safe in recommended amounts for up to 2–3 months (NCCIH). Reported side effects include:
- nausea and vomiting;
- acid reflux and stomach upset;
- diarrhea or constipation;
- hives or itching with topical use.
In the single-dose study up to 12,000 mg, 7 of 24 volunteers (30%) had minimal side effects that were not dose-related (Lao et al. 2006). NCCIH states that turmeric supplements during pregnancy may be unsafe.
Liver injury
The NIH’s LiverTox database states that turmeric and curcumin are linked to a low rate of transient liver enzyme rises, and that some turmeric products “have recently been implicated in several dozen instances of clinically apparent acute liver injury” (LiverTox: Turmeric). NCCIH specifically warns that highly bioavailable curcumin formulations may harm the liver.
US Drug-Induced Liver Injury Network (DILIN). A 2023 case series reviewed every DILIN case from 2004 to 2022 in which turmeric was implicated (Halegoua-DeMarzio et al., Am J Med 2023):
| Feature | Finding |
|---|---|
| Cases | 10, all enrolled since 2011 and 6 since 2017 |
| Patients | 8 women; median age 56 (range 35–71) |
| Reasons for use | Mostly arthritis, pain relief and general well-being |
| Pattern | Hepatocellular (liver-cell) injury in 9, mixed in 1 |
| Time to onset | Typically 1–4 months; median 84 days to symptoms |
| Peak ALT (liver enzyme), median | 1,392 U/L |
| Outcome | 5 hospitalized; 1 died of acute liver failure |
| Product testing | Turmeric confirmed in all 7 products tested; 3 also contained piperine; no other common liver toxins found |
| Genetics | 7 of 10 carried HLA-B*35:01, allele frequency 0.45 vs 0.056–0.069 in population controls |
HLA-B*35:01 is an immune-system gene variant also linked to liver injury from green tea extract and other botanicals, which suggests an immune-mediated, idiosyncratic reaction. The authors suggested the rise in cases may reflect growing use and more frequent combination with black pepper.
Italy. In the first six months of 2019, the Italian Phytovigilance system received a cluster of 28 reports of acute hepatitis, mostly cholestatic (bile-flow) injury, linked to turmeric supplements; this led to regulatory action (Menniti-Ippolito et al., Ann Ist Super Sanita 2020). A detailed analysis of 7 cases from Tuscany found that all involved Curcuma longa formulations “with high bioavailability and high dosage” of curcuminoids, and most improved after stopping the product (Lombardi et al., Br J Clin Pharmacol 2021). The same paper reviewed 23 published cases; most of those patients were also taking at least one other medication, and 16 improved after stopping.
LiverTox counts several dozen clinically apparent cases, a small number given how commonly turmeric is used. But the reports show it is not “liver safe” in every person, and the injury can be severe.
Interactions
Nelson et al. note that curcumin and its breakdown products react with cytochrome P450 enzymes, hERG potassium channels and glutathione S-transferase in laboratory studies (Nelson et al. 2017). These are in-vitro findings, and their importance at the low blood levels reached in people is unclear. Formulations that raise absorption, and piperine itself, change how the body handles curcumin, so their interaction profile may differ from plain turmeric. NCCIH advises discussing herbal products with a health care provider when taking any medicine.
Quality and contamination
Lead chromate in turmeric spice
Lead chromate is a bright yellow industrial pigment. It has been added to turmeric roots during polishing to make poor-quality roots look brighter and sell for more.
- Bangladesh, 2019. Researchers found evidence of lead chromate adulteration in 7 of the 9 major turmeric-producing districts. Turmeric powder contained up to 1,152 μg/g lead, and the pigments used contained 2–10% lead by weight. Wholesalers said the practice had gone on for more than 30 years (Forsyth et al., Environ Res 2019).
- Bangladesh, after intervention. Media coverage, education and enforcement by the Bangladesh Food Safety Authority cut the share of market samples with detectable lead from 47% in 2019 to 0% in 2021. Blood lead in mill workers fell by a median of 30% (Forsyth et al., Environ Res 2023).
- South Asia, 2024. Of 356 samples from 23 cities in India, Pakistan, Sri Lanka and Nepal, 14% had detectable lead above 2 μg/g. Samples from Patna (India), Karachi and Peshawar (Pakistan) exceeded 1,000 μg/g (Forsyth et al., Sci Total Environ 2024).
Cases and recalls in the United States
A 2017 review documented childhood lead poisoning cases linked to spices including turmeric, and voluntary recalls of 13 brands of lead-contaminated turmeric in the preceding years. One recall was a turmeric dietary supplement. In Boston-area testing of 32 store-bought samples, the two samples imported from Bangladesh had 34.8 and 99.5 ppm lead (Cowell et al., Public Health Rep 2017).
In Las Vegas in 2019, a 2-year-old boy had a blood lead level of 48 μg/dL and needed chelation therapy. Turmeric in his home contained 2,000 mg/kg lead. Turmeric in a relative’s home, where another child was also poisoned, contained 3,000 and 15,000 mg/kg (Kappel et al., MMWR 2021).
These reports concern mainly loose or imported spice. They show that turmeric quality depends heavily on the supply chain, and that the bright color of a powder is not a sign of purity.
Key takeaways
- Curcumin is barely absorbed. Single doses up to 8,000 mg left no measurable curcumin in the blood; what circulates is mostly glucuronide and sulfate metabolites with a half-life of about 7 hours.
- “Enhanced” formulations raise blood levels, not proven benefit. Reported increases range from about 1.3-fold to 185-fold, using different methods and often industry funding.
- A serious scientific critique stands. Nelson et al. 2017 classified curcumin as a PAINS and IMPS compound and argued that much of its lab activity reflects assay interference and instability.
- Clinical evidence is modest. Knee osteoarthritis pain shows the most consistent benefit, from heterogeneous trials of moderate quality; results for muscle soreness are inconsistent.
- Liver injury is rare but real. DILIN and Italian reports describe acute hepatitis, including one death, often with high-bioavailability or piperine-containing products and a strong link to HLA-B*35:01.
- The spice can contain lead. Lead chromate adulteration is documented across South Asia and has caused childhood lead poisoning in the United States.
Sources
- Nelson KM, Dahlin JL, Bisson J, et al. The Essential Medicinal Chemistry of Curcumin. J Med Chem. 2017;60(5):1620–1637. PubMed.
- National Center for Complementary and Integrative Health. Turmeric. Last updated April 2025. NCCIH.
- National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Turmeric. Updated June 16, 2025. NCBI Bookshelf.
- Lao CD, Ruffin MT 4th, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10. PubMed.
- Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1411–1417. PubMed.
- Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–356. PubMed.
- Schiborr C, Kocher A, Behnam D, et al. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014;58(3):516–527. PubMed.
- Jäger R, Lowery RP, Calvanese AV, et al. Comparative absorption of curcumin formulations. Nutr J. 2014;13:11. PubMed.
- Wang Z, Singh A, Jones G, et al. Efficacy and Safety of Turmeric Extracts for the Treatment of Knee Osteoarthritis: a Systematic Review and Meta-analysis of Randomised Controlled Trials. Curr Rheumatol Rep. 2021;23(2):11. PubMed.
- Wang Z, Jones G, Winzenberg T, et al. Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis: A Randomized Trial. Ann Intern Med. 2020;173(11):861–869. PubMed.
- Fang W, Nasir Y. The effect of curcumin supplementation on recovery following exercise-induced muscle damage and delayed-onset muscle soreness: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2021;35(4):1768–1781. PubMed.
- Oxley RA, Peart DJ. The effect of curcumin supplementation on functional strength outcomes and markers of exercise-induced muscle damage: A systematic review and meta-analysis. Nutr Health. 2024;30(1):77–92. PubMed.
- Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. 2023;136(2):200–206. PubMed.
- Menniti-Ippolito F, Ippoliti I, Pastorelli AA, et al. Turmeric (Curcuma longa L.) food supplements and hepatotoxicity: an integrated evaluation approach. Ann Ist Super Sanita. 2020;56(4):462–469. PubMed.
- Lombardi N, Crescioli G, Maggini V, et al. Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports. Br J Clin Pharmacol. 2021;87(3):741–753. PubMed.
- Forsyth JE, Nurunnahar S, Islam SS, et al. Turmeric means “yellow” in Bengali: Lead chromate pigments added to turmeric threaten public health across Bangladesh. Environ Res. 2019;179(Pt A):108722. PubMed.
- Forsyth JE, Baker M, Nurunnahar S, et al. Food safety policy enforcement and associated actions reduce lead chromate adulteration in turmeric across Bangladesh. Environ Res. 2023;232:116328. PubMed.
- Forsyth JE, Mistree D, Nash E, et al. Evidence of turmeric adulteration with lead chromate across South Asia. Sci Total Environ. 2024;949:175003. PubMed.
- Cowell W, Ireland T, Vorhees D, et al. Ground Turmeric as a Source of Lead Exposure in the United States. Public Health Rep. 2017;132(3):289–293. PubMed.
- Kappel M, Kraushaar V, Mehretu A, et al. Notes from the Field: Childhood Lead Poisoning Associated with Turmeric Spices - Las Vegas, 2019. MMWR Morb Mortal Wkly Rep. 2021;70(45):1584–1585. PubMed.
- World Anti-Doping Agency. The 2026 Prohibited List. WADA.